Shuo Kang

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Locally Advanced

Renal Cell Carcinoma

Chemotherapy Induced

Top Venues

Expert review of pharmacoeconomics & outcomes research

This page only lists publications with an associated author ORCID identifier.

Publications

Shuo Kang, Jintuo Yin
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Shuo Kang, Jintuo Yin
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis. Expert review of pharmacoeconomics & outcomes research (2024)
Shuo Kang, Jintuo Yin
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis. Expert review of pharmacoeconomics & outcomes research (2024)
Shuo Kang, Huanlong Liu
Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China. Expert review of pharmacoeconomics & outcomes research (2023)